RET
RET (REarranged during Transfection) is a transmembrane receptor tyrosine kinase that is activated by a complex consisting of a soluble glial cell line-derived neurotrophic factor (GDNF) family ligand (GFL) and a glycosyl phosphatidylinositol-anchored co-receptor, GDNF family receptors alpha (GFRalpha).
RET signalling is crucial for the development of the enteric nervous system. RET regulates the development of sympathetic, parasympathetic, motor, and sensory neurons, and is necessary for the postnatal maintenance of dopaminergic neurons. RET also plays a role as a driver oncogene in a variety of human cancers. Fusion of RET with several partner genes has been detected in papillary thyroid, lung, colorectal, pancreatic, and breast cancers, and tyrosine kinase inhibitors (TKIs) for RET (particularly RET-specific inhibitors) show promising effects against such cancers.
All Product Categories
-
RET Related Products (160)
Related Products (160)
-
RET-IN-6
0 ImagesCat. No.: HY-145024CAS No.: 2715208-83-4RET-IN-6 is a potent RET (rearranged during transfection) inhibitor with an IC50 of 4.57 nM (CN113461670A, compound 321).
-
RET V804M Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70779Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804M is a mutant of RET. RET V804M Recombinant Human Active Protein Kinase is a recombinant RET V804M protein that can be used to study RET V804M-related functions.
-
Soxataltinib
0 ImagesCat. No.: HY-159824CAS No.: 2546116-88-3Soxataltinib (example 7) is a potent inhibitor of RET-kinase, with the IC50 of 0.601 nM. Soxataltinib plays an important role in cancer research.
-
RET G691S Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70767Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G691S is a mutant of RET. RET G691S Recombinant Human Active Protein Kinase is a recombinant RET G691S protein that can be used to study RET G691S-related functions.
-
RET G810C Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70768Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G810C is a mutant of RET. RET G810C Recombinant Human Active Protein Kinase is a recombinant RET G810C protein that can be used to study RET G810C-related functions.
-
PLM-101
0 ImagesCat. No.: HY-149539PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3; and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg; po) and an allogeneic xenograft mouse model (dose: 40 mg/kg; po).
-
RET M918T Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70773Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET M918T is a mutant of RET. RET M918T Recombinant Human Active Protein Kinase is a recombinant RET M918T protein that can be used to study RET M918T-related functions.
-
RET R813Q Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70775Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET R813Q is a mutant of RET. RET R813Q Recombinant Human Active Protein Kinase is a recombinant RET R813Q protein that can be used to study RET R813Q-related functions.
-
RET-IN-20
0 ImagesCat. No.: HY-151987CAS No.: 3033547-06-4
-
CDD-2211
0 ImagesCat. No.: HY-176885CAS No.: 3086535-51-2
-
RET-IN-16
0 ImagesCat. No.: HY-146710CAS No.: 2259657-48-0
-
RET-IN-24
0 ImagesCat. No.: HY-153941CAS No.: 2583767-68-2RET-IN-24 (Compound 26) is a selective RET tyrosine kinase inhibitor with antitumor activity.
-
ZW-18-116
0 ImagesCat. No.: HY-180550ZW-18-116 (compound 9) is a dual-target PROTAC degrader for the oncoproteins TRKA and RET. ZW-18-116 induces the degradation of oncoproteins TRKA and RET by recruiting the CRBN E3 ligase. ZW-18-116 exhibits potent anti-proliferative activity in various cancer cell lines harboring RET or TRKA fusions. ZW-18-116 can be used for RET or TRKA-derived cancer research, such as thyroid, lung, and colon cancers.
-
RET-IN-23
0 ImagesCat. No.: HY-153676CAS No.: 2479961-46-9RET-IN-23 (compound 17) is a potent and orally active RET inhibitor with IC50 values of 1.32, 2.50, 6.54, 1.03, 1.47 nM for RET-WT, RET-CCDC6, RET-V804L, RET-V804M, RET-M918T, respectively. RET-IN-23 shows anti-tumor activity.
-
RET/TRKA-IN-1
0 ImagesCat. No.: HY-161775CAS No.: 3048634-52-9
-
RET-IN-25
0 ImagesCat. No.: HY-156113CAS No.: 2965703-02-8RET-IN-25 (compound 6b) is a RET kinase inhibitor with anticancer activity. RET-IN-25 inhibits medullary thyroid carcinoma (MTC) with IC50s of 3.6 μM (3 days) and 3.0 μM (6 days) against TT(C634R) MTC.
-
HSN748
0 ImagesCat. No.: HY-171146CAS No.: 2409925-53-5
